MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryDaily Refresh Schedule
OCX - OncoCyte Corp
$0.99
0.01(0.64%)8:00:00 PM 8/5/2022
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
MarketCap116.3M
PE Ratio
PEG Ratio
P/B4.5
P/S (ttm)206.5
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %5%
Held by Institutions %62%
1 Day Vol Adjusted Return0.2
1 Month Vol Adjusted Return3.2
3 Month Vol Adjusted Return-3.9
6 Month Vol Adjusted Return-9.1
20 Days SMA Price ZScore2.4
50 Days SMA Price ZScore0.2
12 -26 Days PPO-1.2
1 Month Average Short Volume Ratio47.2
1 Day Volume Change ZScore0.2
1 Month Daily Vol3.7
Related Topics
Peers

Related Peers

Stock news

    08/3/2022OCX
    Oncocyte to Participate at Upcoming Investor Conferences

    IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that its management team will participate at the following conferences: UBS Genomics 2.0 and MedTech Innovations SummitPresenting on Thursday, August 11, 2022 at 5:00 p.m. Eastern Time in Dana Point, California. The li

    08/1/2022OCX
    The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable

    Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...

    08/1/2022OCX
    Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022

    IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of John Peter (JP) Gutfreund as an independent member of its board of directors, effective July 28, 2022. “We welcome JP to our Board of Directors at what we believe to be an important time in the life

    07/27/2022OCX
    Oncocyte to Announce Second Quarter 2022 Financial Results

    IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its second quarter 2022 financial results on Wednesday, August 10, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30

    07/13/2022OCX
    Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business

    Oncocyte enters $2B US transplant monitoring market with newly branded VitaGraft™ patented dd-cfDNA technology in two indications, Kidney and Liver Oncocyte initiates IVD Kit Development Process with Global Platform Partners, with plans for US FDA submission IRVINE, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) today announced that it has completed development and clinical validation of the Laboratory Test for its newly-branded VitaGraft™ Transplant Monitoring test

    07/6/2022OCX
    Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022

    Researchers conducted exploratory analysis to find an optimized IO score after validation of original established endpoint was presented at the 2022 ASCO Annual Meeting DetermaIO may help to predict benefit of immunotherapy for the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker IRVINE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by provi

    06/22/2022OCX
    Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice

    IRVINE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), is a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it will host a key opinion leader (KOL) webinar on the role of DetermalO™ and the tumor microenvironment in clinical practice on Tuesday, June 28, 2022, at 10:00am Eastern Time. To register for the webinar, ple

    06/15/2022OCX
    How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own?

    The big shareholder groups in OncoCyte Corporation ( NASDAQ:OCX ) have power over the company. Institutions often own...

    05/26/2022OCX
    Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test’s Potential to Expand the Clinical Use of Immunotherapy

    DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker, addressing a significant unmet need DetermaIO test now validated by 10 studies in six tumor types across four leading immune checkpoint inhibitors IRVINE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights